REGULATED INFORMATION

FINANCIAL STATEMENTS OF THE GROUP & PARENT COMPANY (IN FRENCH)
Company report 2020 Upload
FY2020 financial Annual report Upload
FY2020 ANNUAL ACcOUNTS  (parent company) Upload
HY2020 Financial report – 30 June 2020  Upload

 

fy2019 fINANCIAL ANNUAL REPORT Upload
FY2019 CONSOLIDATED ACCOUNTS Upload
FY2019 ANNUAL ACCOUNTS (parent company) Upload
2019 Company report Upload
HY2019 Financial report – 30 June 2019  Upload
Statutory auditors report on limited review of HY2019 accounts Upload

 

FY2018 Company report Upload
FY2018 ANNUAL financial report Upload
FY2018 consolidated accounts – 31 december 2018 Upload
auditors report on fy2018 consolidated accounts – 31 december 2018 Upload
FY2018 annual accounts – 31 december 2018 Upload
auditors report on fy2018 annual accounts – 31 december 2018 Upload
HY2018 Financial report – 30 June 2018 Upload
Statutory auditors report on limited review of HY2018 accounts Upload
2017 "Document de référence" Upload
FY2017 consolidated accounts – 31 december 2017 Upload
auditors report on fy2017 consolidated accounts – 31 december 2017 Upload
FY2017 annual accounts – 31 december 2017 Upload
auditors report on fy2017 annual accounts – 31 december 2017 Upload
HY2017 Financial report – 30 June 2017 Upload
Statutory auditors report on limited review of HY2017 accounts Upload

 

2016 "Document de référence" Upload
2016 Management report & analysis Upload
FY2016 consolidated accounts Upload
Statutory auditors report on the FY2016 consolidated accounts Upload
Statutory auditors report on the 2016 regulated agreements Upload
FY2016 statutory accounts of parent company Upload
Statutory auditors report on the FY 2016 accounts of parent company Upload
HY2016 Financial report - 30/06/2016 Upload
Statutory Auditors report on HY2016 accounts as at 30 June Upload

 

2015 "Document de référence" Upload
2015 Management report & analysis Upload
FY2015 consolidated accounts Upload
Statutory auditors report on the FY2015 consolidated accounts Upload
Statutory auditors report on the 2015 regulated agreements Upload
FY2015 statutory accounts of parent company Upload
FY2015 statutory accounts of parent company Upload
HY2015 Financial report - 30/06/2015 Upload
Statutory auditors report on limited review of HY2015 accounts Upload

 

DROITS DE VOTE ET ACTIONS
Information concernant le nombre d'actions et de droits de vote (Article L. 233-8 II du Code de commerce, art. 55 de loi)

 

DATE OUSTANDING SHARES NUMBER OF THEORICAL VOTING RIGHTS
31 may 2021 20,134,732 20,138,614
30 april 2021 18,413,990 18,417,870
31 march 2021 16,600,685 16,604,473
28 February 201 14,200,567 14,204,324
31 JANUARY 2021 11,626,515 11,633,553

Tracking the number of shares outstanding

See the chart of outstanding shares in connection with OCABSA in favor of Global Corporate Finance Opportunities

  • This chart (in French) tracks the number of oustanding shares in connection with the issuance of 650 convertible notes into new shares (OCA) in favor of Global Tech Opportunities

See the chart of outstanding shares in connection with OCA in favor of Global Tech Opportunities

  • This chart (in French) tracks the number of oustanding shares in connection with the financing through issuance and subscription of convertible notes into new shares (OCA) with attached warrants (BSA) in favor of European High Growth Opportunities Securitization Fund as described in the press release of 06/09/2019.

See the chart of outstanding shares in connection with OCABSA in favor of European High Growth Opportunities Securitization Fund

  • This chart (in French) tracks the number of oustanding shares in connection with the financing through issuance and subscription of convertible notes into new shares (OCA) with attached warrants (BSA) in favor of Zigi Capital as described in the press release of 24/06/2019.

See the chart of outstanding shares in connection with OCABSA in favor of Zigi Capital

  • This chart (in French) tracks the number of outstanding shares in connection with the financing through issuance and subscritption of warrants giving access to convertible notes into new shares (BEOCA) in favor of European High Growth Opportunities Securitization Fund (EHGOS) as described in the press release of 09/02/2018.

See the chart of oustanding shares in connection with BEOCA in favor of EHGOS

  • This chart (in French) tracks the number of outstanding shares in connection with the flexible bond financing (OCABSA) in favor of Bracknor Fund as described in the press release of 21/07/2016.

See the chart of oustanding shares in connection with OCABSA in favor of Bracknor

 

DATE OUSTANDING SHARES NUMBER OF THEORICAL VOTING RIGHTS
31 december 2020 10,445,969 10,452,493
30 november 2020 9,511,342 9,514,697
31 october 2020 8,214,463 8,225,009
30 september 2020 8,219,736 8,224,997
31 august 2020 8,219,736 8,224,993
31 july 2020 7,301,884* 7,307,115*
30 June 2020 9,110,486,000 9,121,957,548
31 may 2020 9,110,486,000 9,121,891,744
30 avril 2020 6,277,154,950 6,288,563,124
31 mars 2020 3,906,694,405 3,918,104,730
29 February 2020 2,518,527,739 2,529,708,683
31 JANUARY 2020 1,113,676,495 1,124,301,607

* On 07/06/2020, the Company proceeded with a consolidation of shares at the rate of 1 new share against 2,000 old (see the press release - in French)

Tracking the number of shares outstanding

  • This chart (in French) tracks the number of oustanding shares in connection with the issuance of 650 convertible notes into new shares (OCA) in favor of Global Tech Opportunities

See the chart of outstanding shares in connection with OCA in favor of Global Tech Opportunities

  • This chart (in French) tracks the number of oustanding shares in connection with the financing through issuance and subscription of convertible notes into new shares (OCA) with attached warrants (BSA) in favor of European High Growth Opportunities Securitization Fund as described in the press release of 06/09/2019.

See the chart of outstanding shares in connection with OCABSA in favor of European High Growth Opportunities Securitization Fund

  • This chart (in French) tracks the number of oustanding shares in connection with the financing through issuance and subscription of convertible notes into new shares (OCA) with attached warrants (BSA) in favor of Zigi Capital as described in the press release of 24/06/2019.

See the chart of outstanding shares in connection with OCABSA in favor of Zigi Capital

  • This chart (in French) tracks the number of outstanding shares in connection with the financing through issuance and subscritption of warrants giving access to convertible notes into new shares (BEOCA) in favor of European High Growth Opportunities Securitization Fund (EHGOS) as described in the press release of 09/02/2018.

See the chart of oustanding shares in connection with BEOCA in favor of EHGOS

  • This chart (in French) tracks the number of outstanding shares in connection with the flexible bond financing (OCABSA) in favor of Bracknor Fund as described in the press release of 21/07/2016.

See the chart of oustanding shares in connection with OCABSA in favor of Bracknor

 

DATE OUSTANDING SHARES NUMBER OF THEORICAL VOTING RIGHTS
31 december 2019 855,655,396 865,759,033
30 November 2019 662,204,586 672,425,334
31 October 2019 541,263,576 551,489,608
30 SEPTEMBER 2019 487,122,715 497,301,400
31 august 2019 422,997,376 431,226,055
31 july 2019 376,518,555 384,982,751
30 June 2019 339,335,330 347,879,636
31 maY 2019 285,061,,997 292,628,687
30 avril 2019 285,061,997 292,628,687
31 March 2019 285,062,024 292,628,737
28 february 2019 284,480,024 292,040,101
31 JANUARY 2019 284,480,024 292,135,168

Déclaration of transactions on securities

Zigi Capital represented by Jérôme Garnache-Creuillot, Chairman & C.E.O. see the declaration

Zigi Capital  represented by Jérôme Garnache-Creuillot, Chairman & C.E.O. see the declaration

Zigi Capital represented by Jérôme Garnache-Creuillot, Chairman & C.E.O. see the declaration

Tracking the number of shares outstanding

  • This chart (in French) tracks the number of oustanding shares in connection with the financing through issuance and subscription of convertible notes into new shares (OCA) with attached warrants (BSA) in favor of European High Growth Opportunities Securitization Fund as described in the press release of 06/09/2019.

See the chart of outstanding shares in connection with OCABSA in favor of European High Growth Opportunities Securitization Fund

  • This chart (in French) tracks the number of oustanding shares in connection with the financing through issuance and subscription of convertible notes into new shares (OCA) with attached warrants (BSA) in favor of Zigi Capital as described in the press release of 24/06/2019.

See the chart of outstanding shares in connection with OCABSA in favor of Zigi Capital

  • This chart (in French) tracks the number of outstanding shares in connection with the financing through issuance and subscritption of warrants giving access to convertible notes into new shares (BEOCA) in favor of European High Growth Opportunities Securitization Fund (EHGOS) as described in the press release of 09/02/2018.

See the chart of oustanding shares in connection with BEOCA in favor of EHGOS

  • This chart (in French) tracks the number of outstanding shares in connection with the flexible bond financing (OCABSA) in favor of Bracknor Fund as described in the press release of 21/07/2016.

See the chart of oustanding shares in connection with OCABSA in favor of Bracknor

DATE OUSTANDING SHARES NUMBER OF THEORICAL VOTING RIGHTS
31 December 2018 284,476,788 292,132,697
30 November 2018 265,429,602 273,077,215
31 OCTOBER 2018 254,229,532 261,889,915
30 september 2018 245,428,844 253,068,690
31 august 2018 231,510,121 239,112,084
31 JULY 2018 213,009,946 220,563,205
30 June 2018 202,411,869 209,968,033
31 May 2018 199,810,892 207,341,307
30 April 2018 183,908,788 192,123,096
31 MArCH 2018 179,255,357 187,293,012
28 FEBRuary 2018 166,206,577 174,251,173
31 january 2018 152,970,026 161,486,914

Tracking the number of shares outstanding

This chart (in French) tracks the number of outstanding shares in connection with the financing through issuance and subscritption of warrants giving access to convertible notes into new shares (BEOCA) as described in the press release of 09/02/2018.

See the chart of shares oustanding in connection with BEOCA

Tracking the number of shares outstanding

This chart (in French) tracks the number of outstanding shares in connection with the flexible bond financing (OCABSA) as described in the press release of 21/07/2016.

See the chart of shares oustanding in connection with OCABSA

DATE OUSTANDING SHARES NUMBER OF THEORICAL VOTING RIGHTS
31 DECEMber 2017 152,537,636 160,451,671
30 noVEMber 2017 152,519,078 160,444,792
31 october 2017 152,405,521 160,331,705
30 september 2017 152,392,759 160,283,325
31 August 2017 146,963,399 154,858,986
31 July 2017 143,862,922 151,943,073
30 June 2017 139,981,055 148,065,084
31 may 2017 131,077,601 138,980,348
30 April 2017 127,158,554 135,044,557
31 March 2017 127,158,554 135,045,233
28 February 2017 116,415,854 124,267,670
31 January 2017 116,415,854 124,274,214

Tracking the number of shares outstanding

This chart (in French) tracks the number of outstanding shares in connection with the flexible bond financing (OCABSA) as described in the press release of 21/07/2016.

See the chart of shares oustanding in connection with OCABSA

DATE OUSTANDING SHARES NUMBER OF THEORICAL VOTING RIGHTS
31 december 2016 111,653,949 119,295,164
30 november 2016 98,798,391 107,641,956
31 october 2016 88,797,840 96,166,029
30 september 2016 83,616,988 90,984,287
31 August 2016 77,075,383 84,636,943
31 July 2016 73,122,269 80,516,074
30 June 2016 72,535,421** 80,659,913
31 may 2016 70,535,400* 78,069,140
30 April 2016 69,667,524 76,449,043
31 March 2016 69,667,524 76,451,564
29 February 2016 69,667,524 76,407,791
31 January 2016 69,667,524 76,072,316

* 750,000 shares issued as part of the Equity Line

** 2,000,000 shares issued as part of the Equity Line See the press release of 25/02/2016

As part of the Equity Line contract, 2,750,000 shares in total have been issued for a gross amount of €1,405,00 i.e. an average price of €0.51/share.

Tracking the number of shares outstanding

This chart (in French) tracks the number of outstanding shares in connection with the flexible bond financing (OCABSA) as described in the press release of 21/07/2016.

See the chart of shares oustanding in connection with OCABSA

DATE OUSTANDING SHARES NUMBER OF THEORICAL VOTING RIGHTS
31 December 2015 69,667,524 75,867,882
30 November 2015 69,427,212 76,173,317
31 October 2015 69,427,212 76,173,426
12 October 2015 69,427,212 76,166,843
30 September 2015 69,370,051 76,109,682
31 August 2015 69,370,051 76,110,821
31 July 2015 69,370,051 76,114,698
16 July 2015 69,370,051 76,119,863
30 June 2015 69,274,211 76,024,023
31 May 2015 69,274,211 75,929,499
18 May 2015 69,274,211 75,928,450
13 May 2015 69,274,211 75,961,449
30 April 2015 69,274,211 75,932,490
31 March 2015 69,044,970 75,702,722
28 February 2015 69,044,970 75,720,253
31 January 2015 69,044,970 75,727,162

Declaration of transaction on shares - François MARCHAL, Director of the Group.
See the declaration

MONTHLY DECLARATION OF TRADING IN OWN SHARES UNDER THE LIQUIDITY CONTRACT
Nature of securities : share Share capital owned directly at the date of publication of the program : 0/0 The Company terminated the liquidity contract on February 5, 2019

Begining of the program 05/03/2012

Balance as at 31/01/2019 : 321,000
Number of shares purchased : 0
Number of shares sold : 321,000

Begining of the program 05/03/2012

Balance as at 31/12/2018 : 324,000
Number of shares purchased : 30,000
Number of shares sold : 33,000

Begining of the program 05/03/2012

Balance as at 30/11/2018 : 220,000
Number of shares purchased : 150,000
Number of shares sold : 46,000

Begining of the program 05/03/2012

Balance as at 31/10/2018 : 329,369
Number of shares purchased : 51,001
Number of shares sold : 160,370

Begining of the program 05/03/2012

Balance as at 30/09/2018 : 255,369
Number of shares purchased : 89,002
Number of shares sold : 15,002

Begining of the program 05/03/2012

Balance as at 31/08/2018 : 302,819
Number of shares purchased : 58,000
Number of shares sold : 105,450

Begining of the program 05/03/2012

Balance as at 31/07/2018 : 294,819
Number of shares purchased : 53,005
Number of shares sold : 45,005

Begining of the program 05/03/2012

Balance as at 30/06/2018 : 249,819
Number of shares purchased : 50,000
Number of shares sold : 5,000

Begining of the program 05/03/2012

Balance as at 30/05/2018 : 263,819
Number of shares purchased : 66,002
Number of shares sold : 80,002

Begining of the program 05/03/2012

Balance as at 30/04/2018 : 251,819
Number of shares purchased : 61,001
Number of shares sold : 49,001

Begining of the program 05/03/2012

Balance as at 31/03/2018 : 156,819
Number of shares purchased : 110,003
Number of shares sold : 15,003

Begining of the program 05/03/2012

Balance as at 28/02/2018 : 201,819
Number of shares purchased : 70,001
Number of shares sold : 115,001

Begining of the program 05/03/2012

Balance as at 31/01/2018 : 211,819
Number of shares purchased : 65,000
Number of shares sold : 75,000

Begining of the program 05/03/2012

Balance as at 31/12/2017 : 200,819
Number of shares purchased : 43,002
Number of shares sold : 32,000

Begining of the program 05/03/2012

Balance as at 30/11/2017 : 232,819
Number of shares purchased : 18,000
Number of shares sold : 50,000

Begining of the program 05/03/2012

Balance as at 31/10/2017 : 221,819
Number of shares purchased : 16,000
Number of shares sold : 5,000

Begining of the program 05/03/2012

Balance as at 30/09/2017 : 235,819
Number of shares purchased : 11,000
Number of shares sold : 25,000

Begining of the program 05/03/2012

Balance as at 31/08/2017 : 231,219
Number of shares purchased : 19,601
Number of shares sold : 15,001

Begining of the program 05/03/2012

Balance as at 31/07/2017 : 198,119
Number of shares purchased : 43,100
Number of shares sold : 10,000

Begining of the program 05/03/2012

Balance as at 30/06/2017 : 182,119
Number of shares purchased : 16,002
Number of shares sold : 2

Begining of the program 05/03/2012

Balance as at 31/05/2017 : 218,205
Number of shares purchased : 51,001
Number of shares sold : 87,087

Begining of the program 05/03/2012

Balance as at 30/04/2017 : 151,005
Number of shares purchased : 84,202
Number of shares sold : 17,002

Begining of the program 05/03/2012

Balance as at 31/03/2016 : 133,127
Number of shares purchased : 44,707
Number of shares sold : 31,578

Begining of the program 05/03/2012

Balance as at 31/03/2017 : 198,005
Number of shares purchased : 55,000
Number of shares sold : 102,000

Begining of the program 05/03/2012

Balance as at 29/02/2016 : 131,127
Number of shares purchased : 57,008
Number of shares sold : 55,008

Begining of the program 05/03/2012

Balance as at 28/02/2017 : 79,940
Number of shares purchased : 155,000
Number of shares sold : 31,935

Begining of the program 05/03/2012

Balance as at 31/01/2017 : 232,825
Number of shares purchased : 35,001
Number of shares sold : 192,886

Begining of the program 05/03/2012

Balance as at 31/12/2016 : 216,025
Number of shares purchased : 106,800
Number of shares sold : 90,000

Begining of the program 05/03/2012

Balance as at 30/11/2016 : 186,025
Number of shares purchased : 90,000
Number of shares sold : 60,000

Begining of the program 05/03/2012

Balance as at 31/10/2016 : 192,970
Number of shares purchased : 125,003
Number of shares sold : 131,948

Begining of the program 05/03/2012

Balance as at 30/09/2016 : 197,970
Number of shares purchased : 75,000
Number of shares sold : 80,000

Begining of the program 05/03/2012

Balance as at 31/08/2016 : 111,205
Number of shares purchased : 115,003
Number of shares sold : 28,238

Begining of the program 05/03/2012

Balance as at 31/07/2016 : 124,205
Number of shares purchased : 72,005
Number of shares sold : 85,005

Begining of the program 05/03/2012

Balance as at 30/06/2016 : 141,014
Number of shares purchased : 118,703
Number of shares sold : 135,512

Begining of the program 05/03/2012

Balance as at 31/05/2016 : 171,305
Number of shares purchased : 55,505
Number of shares sold : 85,796

Begining of the program 05/03/2012

Balance as at 30/04/2016 : 146,256
Number of shares purchased : 47,060
Number of shares sold : 22,011

Begining of the program 05/03/2012

Balance as at 31/01/2016 : 167,227
Number of shares purchased : 53,904
Number of shares sold : 90,004

Begining of the program 05/03/2012

Balance as at 31/12/2015 : 135,227
Number of shares purchased : 47,001
Number of shares sold : 15,001

Begining of the program 05/03/2012

Balance as at 30/11/2015 : 130,227
Number of shares purchased : 115,001
Number of shares sold : 110,001

Begining of the program 05/03/2012

Balance as at 31/10/2015 : 120,753
Number of shares purchased : 108,669
Number of shares sold : 99,195

Begining of the program 05/03/2012

Balance as at 30/09/2015 : 91,803
Number of shares purchased : 116,005
Number of shares sold : 87,055

Begining of the program 05/03/2012

Balance as at 31/08/2015 : 128,858
Number of shares purchased : 87,010
Number of shares sold : 124,065

Begining of the program 05/03/2012

Balance as at 31/07/2015 : 98,141
Number of shares purchased : 71,506
Number of shares sold : 40,789

Begining of the program 05/03/2012

Balance as at 30/06/2015 : 105,566
Number of shares purchased : 26,579
Number of shares sold : 34,004

Begining of the program 05/03/2012

Balance as at 31/05/2015 : 41,366
Number of shares purchased : 135,002
Number of shares sold : 70,802

Begining of the program 05/03/2012

Balance as at 30/04/2015 : 89,926
Number of shares purchased : 35,443
Number of shares sold : 84,003

Begining of the program 05/03/2012

Balance as at 31/03/2015 : 103,207
Number of shares purchased : 80,000
Number of shares sold : 93,281

Begining of the program 05/03/2012

Balance as at 28/02/2015 : 69,423
Number of shares purchased : 151,252
Number of shares sold : 117,468

Begining of the program 05/03/2012

Balance as at 31/01/2015 : 58,695
Number of shares purchased : 149,000
Number of shares sold : 138,272

Begining of the program 05/03/2012

Balance as at 31/12/2014 : 102,620
Number of shares purchased : 186,076
Number of shares sold : 230,001

FINANCIAL PRESS RELEASE

07/06/2021

Number of shares and voting rights as at 31/05/2021

07/06/2021

Ordinary General Meeting of 08/06/2021 : provisional quorum

25/05/2021

Europlasma signs a promise to acquire Tarbes Industry

25/05/2021

Drawdown of 3 tranches of 100 convertible notes with warrants attached

20/05/2021

Inertam continues its collaboration with "Région Auvergne Rhône Alpes" and renews its ambition to develop new capacities for final asbestos waste treatment

19/05/2021

Inertam: new optimization phase of the asbestos waste vitrification line

18/05/2021

Information relative to the Ordinary General Meeting of Shareholders on 08/06/2021

05/05/2021

Number of shares and voting rights as at 30/04/2021

29/04/2021

Europlasma confirms its eligibility for the French PEA-PME regime

28/04/2021

Publication of the FY2020 Financial Annual Report

21/04/2021

Drawdown of 5 tranche of 100 convertible notes with warrants attached

20/04/2021

FY2020 Results

16/04/2021

Set up of bond financing of up to € 100M over 7 years by OCABSA’s issuance to support the second phase of Europlasma's development

02/04/2021

Number of shares and voting rights as at 31/03/2021

19/03/2021

Solid Refused Fuels: First multi-year contract of at least € 4.5 million over 5 years

18/03/2021

Drawdown of the last Tranche 15 of 200 convertible notes

03/03/2021

Number of shares and voting rights as at 28/02/2021

24/02/2021

Extraordinary General Meeting of Shareholders on 24/02/2021 - Results

15/02/2021

Extraordinary General Meeting of Shareholders on 24/02/2021

09/02/2021

First promising results of projects in China

08/02/2021

Information relative to the Extraordinary General Meeting of Shareholders on 24/02/2021

04/02/2021

Information relative to the number of shares and voting rights as at 31/01/2021

27/01/2021

Drawdown of the Tranche 14 of 200 convertible notes

19/01/2021

Extraordinary General Meeting of Shareholders convened on 24/02/2021

06/01/2021

Information relative to the number of shares and voting rights as at 31/12/2020

29/12/2020

Inertam treated 2,300 tonnes of waste along second half of 2020

28/12/2020

Europlasma's deleveraging : issue of 650 convertible bonds for the benefit of Global Tech Opportunities 1 Fund

28/12/2020

Group's deleveraging validated by the Extraordinary General Meeting of Shareholders on 28/12/2020

11/12/2020

Information relative to the Extraordinary General Meeting of Shareholders on 28/12/2020

09/12/2020

Extraordinary General Meeting of Shareholders on 28/12/2020 behind closed doors

08/12/2020

Drawdown of the Tranche 13 of 200 convertible notes

04/12/2020

Information relative to the number of shares and voting rights as at 30/11/2020

20/11/2020

Extraordinary Shareholders' Meeting convened on 18/12/2020 behind closed doors

16/11/2020

Strategic reorientation of the CHO Morcenx site

13/11/2020

Restructuring of CHO Morcenx's debt allowing massive deleveraging of the group

04/11/2020

Information relative to the number of shares and voting rights as at 31/10/2020

03/11/2020

Drawdown of the Tranche 12 of 200 convertible notes

02/11/2020

Hugo Brugière resigns of his mandate as Director

23/10/2020

Postponement of the extraordinary shareholders' meeting convened on 28/10/2020

12/10/2020

2020 Half-Year Results

12/10/2020

Extraordinary General Meeting of Shareholders convened on 28/10/2020

05/10/2020

Information relative to the number of shares and voting rights as at 30/09/2020

15/09/2020

Europlasma and Hangzhou University approve the creation of a research center for the treatment of fly ash and the recycling of aluminum.

03/09/2020

Information relative to the number of shares and voting rights as at 31/08/2020

31/08/2020

Ordinary and extraordinary General Meeting on 31/08/2020 - Quorum not reached, Second General Meeting on 22/09/2020

28/08/2020

Ordinary and extraordinary General Meeting on 31/08/2020 - Provisional quorum

14/08/2020

Call to the ordinary and extraordinary General Meeting on 31/08/2020

06/08/2020

Information relative to the number of shares and voting rights as at 31/07/2020

03/08/2020

Drawdown of the tranche 11 of 200 convertible notes

27/07/2020

Drawdown of the tranche 10 of 200 convertible notes

20/07/2020

Europlasma accelerates the pace of its financing in order to support its development strategy

17/07/2020

Europlasma wants to clean up oil industry

17/07/2020

Europlasma wants to clean up oil industry

15/07/2020

GRTgaz selects EUROPLASMA

07/07/2020

Drawdown of the tranche 8 of 200 convertible notes

06/07/2020

Listing of new shares from reverse stock split and rights' adjustments of other securities.

03/07/2020

Information relative to the number of shares and voting rights as at 30/06/2020

02/07/2020

The National Assembly chooses Europlasma for the treatment of asbestos

01/07/2020

Heating of the Inertam asbestos treatment plant

11/06/2020

Restart of Inertam, a new major step in the strategic plan

08/06/2020

Information relative to the number of shares and voting rights as at 31/05/2020

04/06/2020

Technical informations on Europlasma's shares consolidation

18/05/2020

Europlasma's share consolidation

13/05/2020

Europlasma increases its anchoring in China

07/05/2020

Information relative to the number of shares and voting rights as at 30/04/2020

30/04/2020

Publication of the FY2019 Annual Report

29/04/2020

Drawdown of the tranche 7 of convertible bonds

27/04/2020

Extraodinary Shareholders meeting of 27 April, 2020

27/04/2020

FY2019 Annual Results

20/04/2020

Extraodinary Shareholders meeting of 20 April, 2020

07/04/2020

Information relative to the number of shares and voting rights as at 31/03/2020

06/04/2020

Extraodinary Shareholders meeting of 6 April, 2020

01/04/2020

Extraodinary Shareholders meeting of 6 April, 2020 behind closed doors

18/03/2020

Invitation to the Extraordinary Shareholder's meeting on 6 April, 2020

06/03/2020

Information relative to the number of shares and voting rights as at 29/02/2020

28/02/2020

Consolidation of shares planned and equity financing secured

05/02/2020

Information relative to the number of shares and voting rights as at 31/01/2020

20/01/2020

Haly-year results as as at 30 June 2019

10/01/2020

Information on number of voting rights and shares as at 31/12/2019

08/01/2020

Letter of intent for the final treatment of fly ash for 4 waste incinerators in China

17/12/2019

Cooperation agreement with the city of LaiXi for the deployment of the Group's technologies in China

11/12/2019

Drawdown details on the 3rd tranche of convertible bonds

05/12/2019

Information on number of voting rights and shares as at 30/11/2019

29/11/2019

Ordinary Shareholders' meeting of November 29, 2019

27/11/2019

Europlasma presents its strategic orientation

14/11/2019

Strengthened Management team and new organisation finalized

08/11/2019

Invitation to the ordinary Shareholders' meeting of November 29, 2019.

06/11/2019

Information on number of voting rights and shares as at 31/10/2019

23/10/2019

Renewal eligibility for the French PEA-PME regime

21/10/2019

2018 Annual Results of the Group

18/10/2019

Drawdown of the second tranche of 200 convertible bonds

07/10/2019

Group's activity update

04/10/2019

Information on number of voting rights and shares as at 30/09/2019

17/09/2019

A framework partnership agreement with Orano Cycle has come into effect

06/09/2019

Drawdown of the first tranche of 200 convertible bonds

04/09/2019

Information on number of voting rights and shares as at 31/08/2019

03/09/2019

Issuance of 3,000 warrants given access to notes convertible into shares with shares subscription warrants attached (BEOCABSA)

03/09/2019

General Meeting of Shareholders on 3 September 2019

20/08/2019

General Meeting of Shareholders on 20 August 2019

19/08/2019

Update on the Group's activity

08/08/2019

Zigi capital strengthens its stake in Europlasma

06/08/2019

Information on number of voting rights and shares as at 31/07/2019

02/08/2019

Business continuity plan adopted by the Commercial Court

01/08/2019

General Management strengthened: Olivier Pla appointed as Deputy Chief Executive Officer of the Group

31/07/2019

Invitation to the ordinary and extraordinary Shareholders' meeting of August 20, 2019.

25/07/2019

Date of deliberations of the Commercial Court extended to August 2,2019.

19/07/2019

Conversion of convertible bonds (OCABSA) by Zigi Capital

18/07/2019

16/07/2019 - Commercial Court session: deliberation end of July

03/07/2019

Information on number of voting rights and shares as at 30/06/2019

24/06/2019

First measures to enable setting up the continuation plan

13/06/2019

Information on number of voting rights and shares as at 31/05/2019

04/06/2019

Observation period maintained

13/05/2019

Update on legal proceedings update

06/05/2019

Information on number of voting rights and shares as at 30/04/2019

24/04/2019

Update on legal proceedings progress

16/04/2019

Update on legal proceedings progress

05/04/2019

Details concerning BSAR exercise

04/04/2019

Number of voting rights and shares as at 31/03/2019

26/03/2019

Legal proceedings update

20/03/2019

Trading suspension

12/03/2019

Number of voting rights and shares as at 28/02/2019

13/02/2019

Termination of the liquidity contract

11/02/2019

Number of voting rights and shares as at 31/01/2019

21/01/2019

Europlasma asked Euronext Paris to suspend the trading of its shares (FR0000044810-ALEUP) from today before the opening of the stock exchange.

11/01/2019

Invitation to General Meeting of Shareholders

07/01/2019

Number of shares and voting rights as at 31/12/2018

04/01/2019

Half-year report on liquidity contract as at 31/12/2018

07/12/2018

Update on funding prospects

05/12/2018

Number of shares and voting rights as at 30/11/2018

12/11/2018

Europlasma announces the suspension of the exercise of the 4th warrant given access to convertible bonds.

06/11/2018

Information relative to the number of shares and voting rights as at 31/10/2018

31/10/2018

Half-year consolidated Results as at 30/06/2018

12/10/2018

Reactivation of the financing agreement by issuance of convertible bonds

04/10/2018

Number of shares and voting rights as at 30/09/2018

27/09/2018

General Meeting of Shareholders on 27 September 2018

05/09/2018

Europlasma announces the signature of a partnership framework agreement with Orano Cycle and the progression of discussions with financial investors to have a reference sharholder

04/09/2018

Information relative to number of shares and voting rights as at 31/08/2018

03/09/2018

Europlasma announces the suspension of the exercise of the 3rd warrant given access to convertible bonds.

08/08/2018

Information relative to number of shares and voting rights as at 31st July.

26/07/2018

Update on the commercial activity of the Group

17/07/2018

Renewal of the convertible bond financing agreement

05/07/2018

Information relative to number of shares and voting rights as at 30 June.

04/07/2018

Half-year report on liquidity contract as at 30/06/2018

28/06/2018

Annual General Meeting, new call on 27 September 2018

21/06/2018

Annual General Meeting, new call

21/06/2018

Update on the Group's activity

07/06/2018

Information relative to number of shares and voting rights as at 31 May.

14/05/2018

Information relative to number of shares and voting rights as at 30 April.

27/04/2018

Filing of the 2017 Registration Document ("Document de Référence 2017")

17/04/2018

2017 Annual Results of the Group

13/04/2018

Europlasma announces an agreement with European High Growth Opportunities Securitization Fund improving the conditions of the 3rd tranche of convertible bonds

05/04/2018

Information relative to number of shares and voting rights as at 31 March.

28/03/2018

EIB and Europlasma announce the signature of a € 30 million financing contract for the innovative CHO Tiper project

22/03/2018

Europlasma announces a capital increase in its subsidiary CHO Power, valuing it at €101 million, and a simultaneous reorganisation of CHO Morcenx

05/03/2018

Number of shares and voting rights as at 28/02/2018

26/02/2018

Europlasma commits alongside Arcelor Mittal to reducing the carbon footprint of the steel industry

09/02/2018

Convertible bonds financing contract for a maximum amount of EUR 8 million

06/02/2018

Number of shares and voting rights as at 31/01/2018

10/01/2018

Half-year report on liquidity contract

04/01/2018

Number of shares and voting rights as at 31/12/2017

20/12/2017

BEI announces its intention to support the CHO Tiper project by providing up to 30 million euro

05/12/2017

Number of shares and voting rights as at 30/11/2017

14/11/2017

Information relative to BSAR C

07/11/2017

Number of shares and voting rights as at 31/10/2017

26/10/2017

General Meeting of Shareholders of 26/10/2017

24/10/2017

Half-year results as at 30 June 2017

10/10/2017

General Meeting of Shareholders, new call

10/10/2017

Number of shares and voting rights as at 30/09/2017

26/09/2017

Review of the 2014-2017 Strategy and Growth Perspective

11/09/2017

Number of shares and voting rights as at 31/08/2017

06/09/2017

Delivery of the plasma facility for the treatment of low-level radioactive waste in Bulgaria

23/08/2017

Debt reduction: capital increase by conversion of debts

03/08/2017

Number of shares and voting rights as at 31/07/2017

26/07/2017

Issuance of the last tranche of OCABSA

24/07/2017

Delivery of the vitrification unit for fly ash in China

05/07/2017

Half-year report on liquidity contract

04/07/2017

Number of shares and voting rights as at 30/06/2017

03/07/2017

Issuance of OCABSA Tranche 13

29/06/2017

General Meeting of Shareholders of 29 June 2017

15/06/2017

General Meeting of Shareholders, new call

14/06/2017

Europlasma announces Final Acceptance of the CHO Morcenx plant

13/06/2017

Issuance of OCABSA Tranche 12

07/06/2017

Number of shares and voting rights as at 31/05/2017

06/06/2017

Renewal eligibility for the French PEA-PME regime

30/05/2017

Issuance of OCABSA Tranche 11

15/05/2017

Issuance of OCABSA Tranche 10

05/05/2017

Number of shares and voting rights as at 30/04/2017

28/04/2017

Availability of the 2016 Registration Document

19/04/2017

Europlasma announces its results for the year ended December 31, 2016

10/04/2017

CHO Morcenx power plant: acceptance of the second GE Jenbacher engine

04/04/2017

Number of shares and voting rights as at 31/03/2017

21/03/2017

CHO Morcenx power plant: update on the acceptance of the second GE Jenbacher engine

08/03/2017

Number of shares and voting rights as at 28/02/2017

20/02/2017

CHO Morcenx power plant: acceptance of the first Jenbacher engine successfully performed

09/02/2017

Number of shares and voting rights as at 31/01/2017

23/01/2017

Issuance of OCABSA Tranche 9 / CHO Morcenx power plant update

06/01/2017

HY report on the liquidity contract

22/12/2016

Corporate events

19/12/2016

Update on the different business units

15/12/2016

Issuance of OCABSA Tranche 7

07/11/2016

Nuclear Industry calls on Europlasma once again

26/10/2016

Half-year 2016 Results

31/08/2016

Delivery of the additional engines at CHO Morcenx plant, resumption of production at Inertam, return of Erik Martel within the Board of Directors

21/07/2016

Changes in governance and financing structure

21/07/2016

Activity review

13/07/2016

12M€ support from ADEME

05/07/2016

Half-year report on Europlasma liquidity contract

30/06/2016

Renewal eligibility for the French PEA-PME regime

28/04/2016

Filing of the 2015 Registration Document

21/04/2016

2015 annual results and highlights

20/04/2016

Appointment of Yann Le Doré as independent Director

25/02/2016

2015 Turnover, update on cash position and implementation of equity line financing

25/02/2016

2015 Turnover, update on cash position and implementation of equity line financing

25/01/2016

Order of the additional engines for the CHO Morcenx power plant

07/01/2016

Half-year report as at 31/12/2015 on the liquidity contract

11/12/2015

Private Placement of EUR 5 million

30/11/2015

CHO Power: FAR secured at Morcenx

30/10/2015

Consolidated results at 30 June 2015

09/09/2015

CHO Morcenx: FAR protocol to resume in September

29/07/2015

Renewal of the eligibility for the French PEA-PME regime

27/07/2015

CHO Morcenx: update on "Final Acceptance with Reserves"

02/07/2015

Half-year report as at 30/06/2015 on the liquidity contract

02/06/2015

Filing of the 2014 Registration Document

30/04/2015

2014 Annual Results

23/01/2015

Capital increase by BSAR subscription

16/01/2015

Half-year report as at 31/12/2014 on liquidity contract